Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DENN domain-containing protein 4B (DENND4B) is a cytoplasmic and membrane-associated guanine nucleotide exchange factor (GEF) that functions directly in the regulation of Rab protein signal transduction, especially Rab10. It promotes the exchange of GDP for GTP, switching Rab proteins from their inactive to active forms and supporting vesicle trafficking through the endomembrane system, with main localization in the Golgi apparatus and nucleoplasm. Human DENND4B has been linked with rare inherited disorders and is expressed in many tissues. Although some cancer-related data exist, DENND4B is not yet an established therapeutic target, and no drugs specifically target this protein[1][4][10][6][7].
Not applicable, as no direct drugs are known for this target. Theoretical mechanism for possible inhibitors: block GEF activity and Rab activation, thus inhibiting vesicular transport and signal transduction by interfering with GDP-GTP exchange on Rab proteins.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DENN domain-containing protein 4B (DENND4B).